Constitutive ligand-independent Hh pathway activation driven by inactivating mutations in PTCH1 and oncogenic mutations in SMO are described in small number of human malignancies, including SHH-driven medulloblastoma and basal cell carcinoma, and can be effectively treated using small molecule SMO inhibitors [3]. Here, SMO is linked to basal cell carcinoma.